Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The product has been in-licensed from Strides and will be commercialized by Amneal
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Lack of technology transfer stands out as a formidable barrier
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Subscribe To Our Newsletter & Stay Updated
